Multiplicom Receives CE-IVD Mark for Ovarian Cancer CDx Test | GenomeWeb

NEW YORK (GenomeWeb) – Molecular diagnostic firm Multiplicom of Belgium has received the CE-IVD mark for its BRCA Tumor MASTR Plus Dx test, the first ovarian cancer companion diagnostic test to receive this designation in Europe, the company said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.